Current developments in gene therapy for amyotrophic lateral sclerosis

Bibliography

• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72(2):245-56
   PubMed Web of Science ®Google Scholar
• Cooper-Knock J, Shaw PJ, Kirby J. The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol 2014;127(3):333-45
   PubMed Web of Science ®Google Scholar
• Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014;17(1):17-23
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362(6415):59-62
   PubMed Web of Science ®Google Scholar
• Bennion Callister J, Pickering-Brown SM. Pathogenesis/genetics of frontotemporal dementia and how it relates to ALS. Exp Neurol 2014;262:84-90
   PubMed Web of Science ®Google Scholar
• Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72(2):257-68
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol 2014;13(11):1127-38
   PubMed Web of Science ®Google Scholar
• Cideciyan AV, Hauswirth WW, Aleman TS, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 2009;20(9):999-1004
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365(25):2357-65
   PubMed Web of Science ®Google Scholar
• Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006;12(22):6737-47
   PubMed Web of Science ®Google Scholar
• Federici T, Boulis NM. Gene therapy for amyotrophic lateral sclerosis. Neurobiol Dis 2012;48(2):236-42
   PubMed Web of Science ®Google Scholar
• Nizzardo M, Simone C, Falcone M, et al. Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis. Cell Mol Life Sci 2012;69(10):1641-50
   PubMed Web of Science ®Google Scholar
• Ajroud-Driss S, Siddique T. Sporadic and hereditary amyotrophic lateral sclerosis (ALS). Biochim Biophys Acta 2015;1852(4):679-84
   PubMed Web of Science ®Google Scholar
• Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 2013;79(3):416-38
   PubMed Web of Science ®Google Scholar
• Levine TP, Daniels RD, Gatta AT, et al. The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics 2013;29(4):499-503
   PubMed Web of Science ®Google Scholar
• Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012;11(4):323-30
   PubMed Web of Science ®Google Scholar
• Donnelly CJ, Zhang PW, Pham JT, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 2013;80(2):415-28
   PubMed Web of Science ®Google Scholar
• Mori K, Weng SM, Arzberger T, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 2013;339(6125):1335-8
   PubMed Web of Science ®Google Scholar
• Zu T, Liu Y, Banez-Coronel M, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci USA 2013;110(51):E4968-77
   PubMed Web of Science ®Google Scholar
• Ciura S, Lattante S, Le Ber I, et al. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol 2013;74(2):180-7
   PubMed Web of Science ®Google Scholar
• Haeusler AR, Donnelly CJ, Periz G, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature 2014;507(7491):195-200
   PubMed Web of Science ®Google Scholar
• Reddy K, Zamiri B, Stanley SY, et al. The disease-associated r(GGGGCC)n repeat from the C9orf72 gene forms tract length-dependent uni- and multimolecular RNA G-quadruplex structures. J Biol Chem 2013;288(14):9860-6
   PubMed Web of Science ®Google Scholar
• Ash PE, Bieniek KF, Gendron TF, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 2013;77(4):639-46
   PubMed Web of Science ®Google Scholar
• Wen X, Tan W, Westergard T, et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron 2014;84(6):1213-25
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Jansen-West K, Xu YF, et al. Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol 2014;128(4):505-24
   PubMed Web of Science ®Google Scholar
• Kwon I, Xiang S, Kato M, et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 2014;345(6201):1139-45
   PubMed Web of Science ®Google Scholar
• Andersen PM. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr Neurol Neurosci Rep 2006;6(1):37-46
   PubMed Web of Science ®Google Scholar
• Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009;65(Suppl 1):S3-9
   PubMed Web of Science ®Google Scholar
• Saccon RA, Bunton-Stasyshyn RK, Fisher EM, Fratta P. Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain 2013;136(Pt 8):2342-58
   PubMedGoogle Scholar
• Harraz MM, Marden JJ, Zhou W, et al. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J Clin Invest 2008;118(2):659-70
   PubMed Web of Science ®Google Scholar
• Mead RJ, Higginbottom A, Allen SP, et al. S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis. Free Radic Biol Med 2013;61:438-52
   PubMed Web of Science ®Google Scholar
• Watanabe M, Dykes-Hoberg M, Culotta VC, et al. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis 2001;8(6):933-41
   PubMed Web of Science ®Google Scholar
• Bruijn LI, Becher MW, Lee MK, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997;18(2):327-38
   PubMed Web of Science ®Google Scholar
• Bruijn LI, Houseweart MK, Kato S, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998;281(5384):1851-4
   PubMed Web of Science ®Google Scholar
• Johnston JA, Dalton MJ, Gurney ME, Kopito RR. Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2000;97(23):12571-6
   PubMed Web of Science ®Google Scholar
• Forsberg K, Andersen PM, Marklund SL, Brannstrom T. Glial nuclear aggregates of superoxide dismutase-1 are regularly present in patients with amyotrophic lateral sclerosis. Acta Neuropathol 2011;121(5):623-34
   PubMed Web of Science ®Google Scholar
• Forsberg K, Jonsson PA, Andersen PM, et al. Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS One 2010;5(7):e11552
   PubMed Web of Science ®Google Scholar
• Pokrishevsky E, Grad LI, Yousefi M, et al. Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS ONE 2012;7(4):e35050
   PubMed Web of Science ®Google Scholar
• Karch CM, Prudencio M, Winkler DD, et al. Role of mutant SOD1 disulfide oxidation and aggregation in the pathogenesis of familial ALS. Proc Natl Acad Sci USA 2009;106(19):7774-9
   PubMed Web of Science ®Google Scholar
• Tateno M, Kato S, Sakurai T, et al. Mutant SOD1 impairs axonal transport of choline acetyltransferase and acetylcholine release by sequestering KAP3. Hum Mol Genet 2009;18(5):942-55
   PubMed Web of Science ®Google Scholar
• Yu A, Shibata Y, Shah B, et al. Protein aggregation can inhibit clathrin-mediated endocytosis by chaperone competition. Proc Natl Acad Sci USA 2014;111(15):E1481-90
   Google Scholar
• Shaw PJ, Forrest V, Ince PG, et al. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995;4(2):209-16
   PubMedGoogle Scholar
• Cheah BC, Vucic S, Krishnan AV, Kiernan MC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem 2010;17(18):1942-199
   PubMed Web of Science ®Google Scholar
• Trotti D, Rolfs A, Danbolt NC, et al. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci 1999;2(5):427-33
   PubMed Web of Science ®Google Scholar
• Milanese M, Zappettini S, Onofri F, et al. Abnormal exocytotic release of glutamate in a mouse model of amyotrophic lateral sclerosis. J Neurochem 2011;116(6):1028-42
   PubMed Web of Science ®Google Scholar
• Giribaldi F, Milanese M, Bonifacino T, et al. Group I metabotropic glutamate autoreceptors induce abnormal glutamate exocytosis in a mouse model of amyotrophic lateral sclerosis. Neuropharmacology 2013;66:253-63
   PubMed Web of Science ®Google Scholar
• Milanese M, Giribaldi F, Melone M, et al. Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2014;64:48-59
   PubMed Web of Science ®Google Scholar
• Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995;14(6):1105-16
   PubMed Web of Science ®Google Scholar
• Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 1998;18(9):3241-50
   PubMed Web of Science ®Google Scholar
• Pickles S, Destroismaisons L, Peyrard SL, et al. Mitochondrial damage revealed by immunoselection for ALS-linked misfolded SOD1. Hum Mol Genet 2013;22(19):3947-59
   PubMed Web of Science ®Google Scholar
• Pasinelli P, Belford ME, Lennon N, et al. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 2004;43(1):19-30
   PubMed Web of Science ®Google Scholar
• Pramatarova A, Laganiere J, Roussel J, et al. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci 2001;21(10):3369-74
   PubMed Web of Science ®Google Scholar
• Lino MM, Schneider C, Caroni P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J Neurosci 2002;22(12):4825-32
   PubMed Web of Science ®Google Scholar
• Gong YH, Parsadanian AS, Andreeva A, et al. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J Neurosci 2000;20(2):660-5
   PubMed Web of Science ®Google Scholar
• Sobue G, Hashizume Y, Yasuda T, et al. Phosphorylated high molecular weight neurofilament protein in lower motor neurons in amyotrophic lateral sclerosis and other neurodegenerative diseases involving ventral horn cells. Acta Neuropathol 1990;79(4):402-8
   PubMed Web of Science ®Google Scholar
• Rouleau GA, Clark AW, Rooke K, et al. SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis. Ann Neurol 1996;39(1):128-31
   PubMed Web of Science ®Google Scholar
• Tu PH, Raju P, Robinson KA, et al. Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci USA 1996;93(7):3155-60
   PubMed Web of Science ®Google Scholar
• Williamson TL, Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci 1999;2(1):50-6
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314(5796):130-3
   PubMed Web of Science ®Google Scholar
• Yang C, Wang H, Qiao T, et al. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2014;111(12):E1121-9
   PubMed Web of Science ®Google Scholar
• Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008;319(5870):1668-72
   PubMed Web of Science ®Google Scholar
• Kabashi E, Valdmanis PN, Dion P, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008;40(5):572-4
   PubMed Web of Science ®Google Scholar
• Kwiatkowski TJJr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009;323(5918):1205-8
   PubMed Web of Science ®Google Scholar
• Vance C, Rogelj B, Hortobagyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009;323(5918):1208-11
   PubMed Web of Science ®Google Scholar
• Vance C, Scotter EL, Nishimura AL, et al. ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Hum Mol Genet 2013;22(13):2676-88
   PubMed Web of Science ®Google Scholar
• Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010;50:259-93
   PubMed Web of Science ®Google Scholar
• Ralph GS, Radcliffe PA, Day DM, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005;11(4):429-33
   PubMed Web of Science ®Google Scholar
• Raoul C, Abbas-Terki T, Bensadoun JC, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005;11(4):423-8
   PubMed Web of Science ®Google Scholar
• Foust KD, Salazar DL, Likhite S, et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther 2013;21(12):2148-59
   PubMed Web of Science ®Google Scholar
• Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006;116(8):2290-6
   PubMed Web of Science ®Google Scholar
• Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 2013;12(5):435-42
   PubMed Web of Science ®Google Scholar
• Lagier-Tourenne C, Baughn M, Rigo F, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci USA 2013;110(47):E4530-9
   PubMed Web of Science ®Google Scholar
• Rodriguez-Ithurralde D, Maruri A, Rodriguez X. Motor neurone acetylcholinesterase release precedes neurotoxicity caused by systemic administration of excitatory amino acids and strychnine. J Neurol Sci 1998;160(Suppl 1):S80-6
   Google Scholar
• Marc G, Leah R, Ofira E, et al. Presymptomatic treatment with acetylcholinesterase antisense oligonucleotides prolongs survival in ALS (G93A-SOD1) mice. Biomed Res Int 2013;2013:845345
   Google Scholar
• Andres C, Beeri R, Friedman A, et al. Acetylcholinesterase-transgenic mice display embryonic modulations in spinal cord choline acetyltransferase and neurexin Ibeta gene expression followed by late-onset neuromotor deterioration. Proc Natl Acad Sci USA 1997;94(15):8173-8
   PubMed Web of Science ®Google Scholar
• Festoff BW. Release of acetylcholinesterase in amyotrophic lateral sclerosis. Adv Neurol 1982;36:503-17
   PubMedGoogle Scholar
• Walsh MJ, Cooper-Knock J, Dodd JE, et al. Invited review: decoding the pathophysiological mechanisms that underlie RNA dysregulation in neurodegenerative disorders: a review of the current state of the art. Neuropathol Appl Neurobiol 2015;41(2):109-34
   PubMed Web of Science ®Google Scholar
• Goodall EF, Heath PR, Bandmann O, et al. Neuronal dark matter: the emerging role of microRNAs in neurodegeneration. Front Cell Neurosci 2013;7:178
   PubMed Web of Science ®Google Scholar
• Koval ED, Shaner C, Zhang P, et al. Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum Mol Genet 2013;22(20):4127-35
   PubMed Web of Science ®Google Scholar
• Lentz TB, Gray SJ, Samulski RJ. Viral vectors for gene delivery to the central nervous system. Neurobiol Dis 2012;48(2):179-88
   PubMed Web of Science ®Google Scholar
• Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004;429(6990):413-17
   PubMed Web of Science ®Google Scholar
• Wang Y, Mao XO, Xie L, et al. Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J Neurosci 2007;27(2):304-7
   PubMed Web of Science ®Google Scholar
• Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005;8(1):85-92
   PubMed Web of Science ®Google Scholar
• Krakora D, Mulcrone P, Meyer M, et al. Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat model. Mol Ther 2013;21(8):1602-10
   PubMed Web of Science ®Google Scholar
• Kadoyama K, Funakoshi H, Ohya W, Nakamura T. Hepatocyte growth factor (HGF) attenuates gliosis and motoneuronal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALS. Neurosci Res 2007;59(4):446-56
   PubMed Web of Science ®Google Scholar
• Suzuki M, McHugh J, Tork C, et al. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther 2008;16(12):2002-10
   PubMed Web of Science ®Google Scholar
• Wang LJ, Lu YY, Muramatsu S, et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci 2002;22(16):6920-8
   PubMed Web of Science ®Google Scholar
• Dodge JC, Haidet AM, Yang W, et al. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol Ther 2008;16(6):1056-64
   PubMed Web of Science ®Google Scholar
• Dodge JC, Treleaven CM, Fidler JA, et al. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol Ther 2010;18(12):2075-84
   PubMed Web of Science ®Google Scholar
• Kaspar BK, Llado J, Sherkat N, et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003;301(5634):839-42
   PubMed Web of Science ®Google Scholar
• Henriques A, Pitzer C, Dittgen T, et al. CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit. Mol Ther 2011;19(2):284-92
   PubMed Web of Science ®Google Scholar
• Pitzer C, Kruger C, Plaas C, et al. Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain 2008;131(Pt 12):3335-47
   PubMed Web of Science ®Google Scholar
• Lepore AC, Haenggeli C, Gasmi M, et al. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res 2007;1185:256-65
   PubMed Web of Science ®Google Scholar
• Franz CK, Federici T, Yang J, et al. Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiol Dis 2009;33(3):473-81
   PubMed Web of Science ®Google Scholar
• Lewis CM, Suzuki M. Therapeutic applications of mesenchymal stem cells for amyotrophic lateral sclerosis. Stem Cell Res Ther 2014;5(2):32
   PubMedGoogle Scholar
• Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS). 2012. Available from: https://clinicaltrials.gov/ct2/show/NCT00748501?term=ALS&rank=5 [Last accessed 13 February 2015]
   Google Scholar
• Plasmid Gene Transfer of Zinc Finger Protein VEGF-A Transcription Activator (SB-509) for Treatment of Amyotrophic Lateral Sclerosis (ALS) - a Phase 2 Clinical Trial, 2012 13 February 2015. Available from: http://informahealthcare.com/userimages/ContentEditor/1407429668697/Guidelines%20EOBT.pdf [Last accessed I13 February 2015]
   Google Scholar
• Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis. 2014-2015. Available from: https://clinicaltrials.gov/ct2/show/NCT02039401?term=vm202&rank=1 [Last accessed 13 February 2015]
   Google Scholar
• Nanou A, Higginbottom A, Valori CF, et al. Viral delivery of antioxidant genes as a therapeutic strategy in experimental models of amyotrophic lateral sclerosis. Mol Ther 2013;21(8):1486-96
   PubMed Web of Science ®Google Scholar
• Gros-Louis F, Soucy G, Lariviere R, Julien JP. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem 2010;113(5):1188-99
   PubMed Web of Science ®Google Scholar
• Patel P, Kriz J, Gravel M, et al. Adeno-associated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis. Mol Ther 2014;22(3):498-510
   PubMed Web of Science ®Google Scholar
• Ayers JI, Fromholt S, Sinyavskaya O, et al. Widespread and Efficient Transduction of Spinal Cord and Brain Following Neonatal AAV Injection and Potential Disease Modifying Effect in ALS Mice. Mol Ther 2015;23(1):53-62
   PubMed Web of Science ®Google Scholar
• Jackson KL, Dayton RD, Orchard EA, et al. Preservation of forelimb function by UPF1 gene therapy in a rat model of TDP-43-induced motor paralysis. Gene Ther 2015;22(1):20-8
   PubMed Web of Science ®Google Scholar
• Aizawa H, Sawada J, Hideyama T, et al. TDP-43 pathology in sporadic ALS occurs in motor neurons lacking the RNA editing enzyme ADAR2. Acta Neuropathol 2010;120(1):75-84
   PubMed Web of Science ®Google Scholar
• Yamashita T, Hideyama T, Hachiga K, et al. A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nat Commun 2012;3:1307
   PubMed Web of Science ®Google Scholar
• Yamashita T, Chai HL, Teramoto S, et al. Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons. EMBO Mol Med 2013;5(11):1710-19
   PubMed Web of Science ®Google Scholar